ArticleOncology letters2015
Glucagonoma syndrome: A case report.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Case report: Surgical treatment and literature review of a recurrent case of glucagonoma.Frontiers in oncology · 2024Article
- Article
- Case of delayed diagnosis of necrolytic migratory erythema.Clinical case reports · 2021Article
- Spleen-preserving distal pancreatectomy and lymphadenectomy for glucagonoma syndrome: A case report.Medicine · 2019Article
- Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management.Case reports in surgery · 2016Article
- Glucagonoma of the pancreas: diagnostic approach and therapeutic algorithm for a rare nosological entity.Annals of gastroenterologyReview
- Diarrhea: a missed D in the 4D glucagonoma syndrome.Autopsy & case reportsArticle
- MANIFESTATIONS OF GLUCAGONOMA SYNDROME.AACE clinical case reportsArticle
- Benign-Appearing Glucagonoma Undergoing Malignant Transformation after a Prolonged Period.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Necrolytic migratory erythema (NME), diabetes mellitus and glucagon-secreting tumors form the hallmarks of glucagonoma syndrome, and represent the major clinical manifestations of glucagonoma. NME is usually presented as the initial complaint of patients. Due to the rare incidence of glucagonoma, its diagnosis is often delayed, which leads to its progression. Here, we report a case of NME with a typical skin rash, which was misdiagnosed and treated with corticosteroids for two years. Removal of the tumor in the pancreatic body led to the rapid relief of the symptoms. The aim of the present study is to demonstrate the typical characteristics of glucagonoma syndrome to clinicians in order to improve its diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.